Lexicon Pharmaceuticals (NASDAQ:LXRX) was upgraded by equities research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a note issued to investors on Tuesday.
Several other analysts have also recently issued reports on LXRX. Zacks Investment Research cut Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 27th. Needham & Company LLC reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Monday, July 30th. Stifel Nicolaus reissued a “buy” rating and issued a $23.00 target price (down previously from $24.00) on shares of Lexicon Pharmaceuticals in a report on Tuesday, July 31st. ValuEngine lowered Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 17th. Finally, Citigroup dropped their target price on Lexicon Pharmaceuticals from $27.00 to $26.00 and set a “buy” rating on the stock in a report on Friday, November 2nd. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $25.25.
Shares of NASDAQ LXRX traded up $0.29 during mid-day trading on Tuesday, hitting $9.14. The company had a trading volume of 4,316 shares, compared to its average volume of 430,180. The stock has a market cap of $902.48 million, a P/E ratio of -7.19 and a beta of 0.73. The company has a current ratio of 2.90, a quick ratio of 2.83 and a debt-to-equity ratio of 8.85. Lexicon Pharmaceuticals has a 1-year low of $7.42 and a 1-year high of $13.97.
A number of large investors have recently bought and sold shares of the stock. Candriam Luxembourg S.C.A. increased its holdings in Lexicon Pharmaceuticals by 36.8% in the third quarter. Candriam Luxembourg S.C.A. now owns 509,000 shares of the biopharmaceutical company’s stock valued at $5,431,000 after buying an additional 137,000 shares during the last quarter. First Trust Advisors LP purchased a new position in Lexicon Pharmaceuticals in the third quarter valued at $1,525,000. Bank of Montreal Can increased its holdings in Lexicon Pharmaceuticals by 8,364.1% in the third quarter. Bank of Montreal Can now owns 122,053 shares of the biopharmaceutical company’s stock valued at $1,302,000 after buying an additional 120,611 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Lexicon Pharmaceuticals by 2.1% during the second quarter. Northern Trust Corp now owns 584,393 shares of the biopharmaceutical company’s stock worth $7,013,000 after purchasing an additional 12,289 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of Lexicon Pharmaceuticals during the second quarter worth about $205,000.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Further Reading: What is a conference call?
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.